TNFRSF8 positive

The patient was treated with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone, following which the febrile episodes improved. This case illustrates an uncommon gastrointestinal-predominant presentation of ALK-negative systemic ALCL presenting as fever of unknown origin. This case underscores the importance of continued diagnostic reassessment and symptom-guided tissue acquisition when conventional staging studies are not initially diagnostic, particularly in patients with a history of indolent lymphoma.

After nivolumab discontinuation and transition to avelumab, the patient experienced complete metabolic resolution of cardiac involvement, improvement in cardiac biomarkers, and durable control of cutaneous lymphoma over more than 3 years of follow-up. This case highlights a temporal association between programmed cell death-1 blockade and atypical dissemination of cutaneous T-cell lymphoma, supported by biologic plausibility, and underscores a potential therapeutic distinction between programmed cell death-1 and programmed death ligand-1 inhibition in malignant T-cell disorders.

P1, N=10, Suspended, University of Alabama at Birmingham | Trial completion date: Jul 2026 --> Jul 2027 | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Jun 2027

BV is a key therapy for CD30-positive CTCL. While real-world experience suggests potential activity in CD30-negative or low disease, prospective trials are needed to define its role in this challenging subgroup.

Current evidence suggests a possible oncogenic interaction between hereditary susceptibility and chronic implant-associated inflammation. Clinicians must maintain vigilance for BIA-ALCL even in prophylactic settings, as early diagnosis and complete surgical excision remain key to favorable outcomes.

P1, N=60, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2026 --> Apr 2027

Most patients (80%) received the BNT162b2 (Pfizer-BioNTech) vaccine...These findings support indeed the need for continued pharmacovigilance among clinicians, especially in patients with prior or latent lymphoproliferative conditions. Nevertheless, these extremely rare and indolent events should not alter the overall favourable risk-benefit profile of COVID-19 vaccination.

P=N/A, N=118, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: May 2027 --> Jun 2026 | Trial primary completion date: May 2027 --> Jun 2026

P=N/A, N=100, Recruiting, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

P=N/A, N=118, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

The patient responded partially to cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) chemotherapy and achieved a complete metabolic response after second-line chemotherapy consisting of dexamethasone, high-dose cytarabine, and carboplatin (DHAC) followed by BEAM-ASCT consolidation. This case highlights diagnostic and therapeutic challenges in atypical presentations of PC-ALCL.